{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:45:48Z","timestamp":1793051148266,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K11912"],"award-info":[{"award-number":["24K11912"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-88033-0","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T11:54:55Z","timestamp":1737806095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Novel treatment strategy targeting interleukin-6 induced by cancer associated fibroblasts for peritoneal metastasis of gastric cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Ema","family":"Mitsui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Okura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Une","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Nishiwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Noma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Ohtsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieko","family":"Ohki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyoshi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"88033_CR1","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 26, 1\u201325. (2023).","DOI":"10.1007\/s10120-022-01331-8"},{"key":"88033_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27\u201340 (2021).","journal-title":"Lancet"},{"key":"88033_CR3","doi-asserted-by":"publisher","first-page":"6037","DOI":"10.3748\/wjg.v26.i39.6037","volume":"26","author":"MH Verstegen","year":"2020","unstructured":"Verstegen, M. H. et al. Metastatic pattern in esophageal and gastric cancer: influenced by site and histology. World J. Gastroenterol. 26, 6037\u20136046 (2020).","journal-title":"World J. Gastroenterol."},{"key":"88033_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2165\/11598890-000000000-00000","volume":"51","author":"C Hasovits","year":"2012","unstructured":"Hasovits, C. & Clarke, S. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. Clin. Pharmacokinet. 51, 203\u2013224 (2012).","journal-title":"Clin. Pharmacokinet."},{"key":"88033_CR5","doi-asserted-by":"publisher","unstructured":"Takahashi, K. et al. Altered intraperitoneal immune microenvironment in patients with peritoneal metastases from gastric cancer. Front. Immunol. 13 https:\/\/doi.org\/10.3389\/fimmu.2022.969468 (2022).","DOI":"10.3389\/fimmu.2022.969468"},{"key":"88033_CR6","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423\u20131437 (2013).","journal-title":"Nat. Med."},{"key":"88033_CR7","doi-asserted-by":"publisher","unstructured":"Yasuda, T. et al. Inflammation-driven senescence-associated secretory phenotype in cancer-associated fibroblasts enhances peritoneal dissemination. Cell. Rep. 34 https:\/\/doi.org\/10.1016\/j.celrep.2021.108779 (2021).","DOI":"10.1016\/j.celrep.2021.108779"},{"key":"88033_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen, X. & Song, E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat. Rev. Drug Discov. 18, 99\u2013115 (2019).","journal-title":"Nat. Rev. Drug Discov"},{"key":"88033_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.omto.2022.04.009","volume":"25","author":"T Ogawa","year":"2022","unstructured":"Ogawa, T. et al. Modulation of p53 expression in cancer-associated fibroblasts prevents peritoneal metastasis of gastric cancer. Mol. Ther. Oncolytics. 25, 249\u2013261 (2022).","journal-title":"Mol. Ther. Oncolytics"},{"key":"88033_CR10","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1080\/15384047.2019.1617566","volume":"20","author":"S Watanabe","year":"2019","unstructured":"Watanabe, S. et al. Photoimmunotherapy for cancer-associated fibroblasts targeting fibroblast activation protein in human esophageal squamous cell carcinoma. Cancer Biol. Ther. 20, 1234\u20131248 (2019).","journal-title":"Cancer Biol. Ther."},{"key":"88033_CR11","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1158\/1078-0432.CCR-18-0205","volume":"24","author":"T Kato","year":"2018","unstructured":"Kato, T. et al. Cancer-associated fibroblasts affect intratumoral CD8(+) and FoxP3(+) T cells via IL6 in the tumor microenvironment. Clin. Cancer Res. 24, 4820\u20134833 (2018).","journal-title":"Clin. Cancer Res."},{"key":"88033_CR12","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s00262-023-03378-7","volume":"72","author":"N Nishiwaki","year":"2023","unstructured":"Nishiwaki, N. et al. Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody. Cancer Immunol. Immunother. 72, 2029\u20132044 (2023).","journal-title":"Cancer Immunol. Immunother"},{"issue":"12","key":"88033_CR13","doi-asserted-by":"publisher","first-page":"e1671760","DOI":"10.1080\/2162402X.2019.1671760","volume":"8","author":"S Sakamoto","year":"2019","unstructured":"Sakamoto, S. et al. Intraperitoneal cancer-immune microenvironment promotes peritoneal dissemination of gastric cancer. Oncoimmunology 8 (12), e1671760. https:\/\/doi.org\/10.1080\/2162402X.2019.1671760 (2019).","journal-title":"Oncoimmunology"},{"key":"88033_CR14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.it.2012.07.003","volume":"33","author":"M Rincon","year":"2012","unstructured":"Rincon, M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol. 33, 571\u2013577 (2012).","journal-title":"Trends Immunol."},{"key":"88033_CR15","doi-asserted-by":"publisher","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","volume":"37","author":"N Kumari","year":"2016","unstructured":"Kumari, N., Dwarakanath, B. S., Das, A. & Bhatt, A. N. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 37, 11553\u201311572 (2016).","journal-title":"Tumour Biol."},{"key":"88033_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.canlet.2016.02.048","volume":"375","author":"R Bharti","year":"2016","unstructured":"Bharti, R., Dey, G. & Mandal, M. Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: a snapshot of IL-6 mediated involvement. Cancer Lett. 375, 51\u201361 (2016).","journal-title":"Cancer Lett."},{"key":"88033_CR17","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3892\/ijo.2015.3122","volume":"47","author":"KA So","year":"2015","unstructured":"So, K. A., Min, K. J., Hong, J. H. & Lee, J. K. Interleukin-6 expression by interactions between gynecologic cancer cells and human mesenchymal stem cells promotes epithelial-mesenchymal transition. Int. J. Oncol. 47, 1451\u20131459 (2015).","journal-title":"Int. J. Oncol."},{"key":"88033_CR18","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1016\/j.febslet.2011.03.023","volume":"585","author":"T Tanaka","year":"2011","unstructured":"Tanaka, T., Narazaki, M. & Kishimoto, T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett. 585, 3699\u20133709 (2011).","journal-title":"FEBS Lett."},{"key":"88033_CR19","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","volume":"77","author":"LJ Scott","year":"2017","unstructured":"Scott, L. J. Tocilizumab: a review in rheumatoid arthritis. Drugs 77, 1865\u20131879 (2017).","journal-title":"Drugs"},{"key":"88033_CR20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/bjc.2013.748","volume":"110","author":"T Nagasaki","year":"2017","unstructured":"Nagasaki, T. et al. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumor angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumor-stroma interaction. Br. J. Cancer. 110, 469\u2013478 (2017).","journal-title":"Br. J. Cancer"},{"key":"88033_CR21","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12885-016-2305-2","volume":"16","author":"M Noguchi-Sasaki","year":"2016","unstructured":"Noguchi-Sasaki, M., Sasaki, Y., Shimonaka, Y., Mori, K. & Fujimoto-Ouchi, K. Treatment with anti-IL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6-producing lung carcinomacells. BMC Cancer. 16, 270. https:\/\/doi.org\/10.1186\/s12885-016-2305-2 (2016).","journal-title":"BMC Cancer"},{"key":"88033_CR22","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-09-0287","volume":"15","author":"S Shinriki","year":"2009","unstructured":"Shinriki, S. et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin. Cancer Res. 15, 5426\u20135434 (2009).","journal-title":"Clin. Cancer Res."},{"key":"88033_CR23","doi-asserted-by":"publisher","unstructured":"Ham, I. H. et al. Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer. Mol Cancer. 18; (2019). https:\/\/doi.org\/10.1186\/s12943-019-0972-8","DOI":"10.1186\/s12943-019-0972-8"},{"key":"88033_CR24","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1158\/0008-5472.CAN-13-1070","volume":"74","author":"JM Lowe","year":"2014","unstructured":"Lowe, J. M. et al. p53 and NF-kappaB coregulate proinflammatory gene responses in human macrophages. Cancer Res. 74, 2182\u20132192 (2014).","journal-title":"Cancer Res."},{"key":"88033_CR25","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.1073\/pnas.1719076115","volume":"115","author":"S Arandkar","year":"2018","unstructured":"Arandkar, S. et al. Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features. Proc. Natl. Acad. Sci. U S A. 115, 6410\u20136415 (2018).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"88033_CR26","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1158\/0008-5472.CAN-12-4150","volume":"73","author":"DE Costea","year":"2013","unstructured":"Costea, D. E. et al. Identification of two distinct carcinoma-associated fibroblast subtypes with differential tumor-promoting abilities in oral squamous cell carcinoma. Cancer Res. 73, 3888\u20133901 (2013).","journal-title":"Cancer Res."},{"key":"88033_CR27","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/1078-0432.CCR-07-1032","volume":"14","author":"WC Liao","year":"2008","unstructured":"Liao, W. C. et al. Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin. Cancer Res. 14, 428\u2013434 (2008).","journal-title":"Clin. Cancer Res."},{"key":"88033_CR28","doi-asserted-by":"publisher","unstructured":"Chen, I. et al. Serum interleukin-6 as a prognostic biomarker for survival in patients with unresectable pancreatic cancer. Ann. Oncol. 27 https:\/\/doi.org\/10.1093\/annonc\/mdw141 (2016).","DOI":"10.1093\/annonc\/mdw141"},{"key":"88033_CR29","first-page":"2702","volume":"6","author":"J Nakashima","year":"2000","unstructured":"Nakashima, J. et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin. Cancer Res. 6, 2702\u20132706 (2000).","journal-title":"Clin. Cancer Res."},{"key":"88033_CR30","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883\u2013899 (2010).","journal-title":"Cell"},{"key":"88033_CR31","doi-asserted-by":"publisher","first-page":"20741","DOI":"10.18632\/oncotarget.15119","volume":"8","author":"X Wu","year":"2017","unstructured":"Wu, X. et al. IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2\/STAT3 signaling pathway. Oncotarget 8, 20741\u201320750 (2017).","journal-title":"Oncotarget"},{"key":"88033_CR32","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1172\/JCI73531","volume":"124","author":"M Rokavec","year":"2014","unstructured":"Rokavec, M. et al. IL-6R\/STAT3\/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J. Clin. Invest. 124, 1853\u20131867 (2014).","journal-title":"J. Clin. Invest."},{"key":"88033_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200806","author":"M Tabuchi","year":"2024","unstructured":"Tabuchi, M. et al. Functional remodeling of intraperitoneal macrophages by oncolytic adenovirus restores anti-tumor immunity for peritoneal metastasis of gastric cancer. Mol. Ther. Oncol. https:\/\/doi.org\/10.1016\/j.omton.2024.200806 (2024).","journal-title":"Mol. Ther. Oncol."},{"key":"88033_CR34","doi-asserted-by":"publisher","first-page":"6829","DOI":"10.3748\/wjg.v22.i30.6829","volume":"22","author":"M Kanda","year":"2016","unstructured":"Kanda, M. & Kodera, Y. Molecular mechanisms of peritoneal dissemination in gastric cancer. World J. Gastroenterol. 22, 6829\u20136840 (2016).","journal-title":"World J. Gastroenterol."},{"key":"88033_CR35","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","volume":"22","author":"G Li","year":"2023","unstructured":"Li, G., Hilgenfeld, R., Whitley, R. & De Clercq, E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat. Rev. Drug Discov. 22, 449\u2013475 (2023).","journal-title":"Nat. Rev. Drug Discov"},{"key":"88033_CR36","first-page":"2430","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain, M. D., Smith, M. & Shah, N. N. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood 141, 2430\u20132442 (2023).","journal-title":"Blood"},{"key":"88033_CR37","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","volume":"14","author":"Japanese Gastric Cancer Association","year":"2011","unstructured":"Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 14, 101\u2013112 (2011).","journal-title":"Gastric Cancer"},{"key":"88033_CR38","doi-asserted-by":"publisher","unstructured":"Ohtsuka, J. et al. Functional loss of p53 cooperates with the in vivo microenvironment to promote malignant progression of gastric cancers. Sci Rep. 8; (2018). https:\/\/doi.org\/10.1038\/s41598-018-20572-1","DOI":"10.1038\/s41598-018-20572-1"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88033-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88033-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88033-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T11:55:01Z","timestamp":1737806101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88033-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["88033"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-88033-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5329166\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]},"assertion":[{"value":"25 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no real or potential conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of potential conflicts of interest"}}],"article-number":"3267"}}